2021
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic
Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opinion On Investigational Drugs 2021, 30: 377-388. PMID: 33622120, PMCID: PMC8194059, DOI: 10.1080/13543784.2021.1880564.Peer-Reviewed Original ResearchConceptsExtrahepatic CCAMinority of patientsComplex molecular landscapePro-oncogenic pathwaysSystematic literature searchDeep phenotyping studyOutcome predictorsExtrahepatic cholangiocarcinomaOverlooked diseaseActionable driversClinical developmentActionable targetsMolecular alterationsOncogenic driversTumor microenvironmentHeterogeneous tumorsLiterature searchDistinct entityMolecular profilingSpecific alterationsMolecular landscapePrecision medicinePerturbed pathwaysImmunotherapyPhenotyping studies
2017
Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview
Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expression 2017, 18: 31-50. PMID: 29070148, PMCID: PMC5860940, DOI: 10.3727/105221617x15088670121925.Peer-Reviewed Original ResearchConceptsMajority of patientsPrimary liver cancerCancer-related deathPotential prognostic relevanceDevelopment of metastasesPro-oncogenic pathwaysNovel druggable targetsMechanism of actionCholangiocarcinoma invasivenessMesenchymal-like phenotypeDevastating malignancyCurative treatmentMolecular mechanismsPoor prognosisPrognostic relevancePrimary tumorBiliary epitheliumLiver cancerUseful biomarkerAbnormal activationCCA cell invasionMost carcinomasCCA cellsTumor microenvironmentCholangiocarcinoma